Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

119.26USD
24 Mar 2017
Change (% chg)

$-1.00 (-0.83%)
Prev Close
$120.26
Open
$120.94
Day's High
$121.43
Day's Low
$118.73
Volume
1,292,350
Avg. Vol
2,542,478
52-wk High
$162.00
52-wk Low
$109.12

Latest Key Developments (Source: Significant Developments)

Arbutus licenses LNP delivery technology to Alexion
Thursday, 16 Mar 2017 05:00pm EDT 

Arbutus Biopharma Corp : Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate . Arbutus Biopharma Corp says under terms of license agreement, Alexion will pay Arbutus $7.5 million upfront . Arbutus Biopharma Corp says Alexion will also make payments of up to $75 million for achievement of development, regulatory, and commercial milestones . Arbutus Biopharma Corp says transaction enables Alexion to address delivery for therapeutic application of messenger RNA . Arbutus Biopharma Corp says transaction also enables Alexion to rapidly enter clinical development with its MRNA product candidate .Arbutus Biopharma - licensed to Alexion Pharma its proprietary lipid nanoparticle technology for exclusive use in one of Alexion's rare disease programs.  Full Article

Alexion Pharma says initiated companywide restructuring
Monday, 13 Mar 2017 05:51pm EDT 

Alexion Pharmaceuticals Inc : Alexion Pharmaceuticals says initiated companywide restructuring . Alexion Pharmaceuticals' spokeswoman says approximately 7% of roles held by Alexion employees across the organization were affected from restructuring Further company coverage: [ALXN.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

FDA accepts sBLA filing of soliris as potential treatment for patients with refractory generalized myasthenia gravis
Wednesday, 8 Mar 2017 06:30am EST 

Alexion Pharmaceuticals Inc - : FDA accepts sBLA filing of soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (GMG) . FDA set a prescription drug user fee act (Pdufa) date of October 23, 2017 .U.S. FDA accepted for review company's supplemental biologics license application to extend indication for soliris.  Full Article

Alexion interim CEO says looking for opportunities in M&A front
Thursday, 16 Feb 2017 12:00pm EST 

Alexion Pharmaceuticals Inc - : Alexion CFO says "we're preparing for potential tax reform": conf call . Alexion chief commercial officer says soliris has broad IP extending into the next decade & expect additional patents in the next 12-18 months: conf call . Alexion interim CEO says previously communicated guidance (from prioir management) for 2018 cannot be relied on, but too early for Co to present new projections . Alexion exec says Co isn't going to add patients to ongoing sbc103 study nor start new studies until "we really understand what's happening" in the trial . Alexion exec says co is unsatisfied with kanuma launch uptake thus far, hurt primarily by low diagnostic testing rates . Alexion interim CEO: "I'm 150% committed to the interim role because it doesn't feel interim. I can tell you that, but I'm all-in." . Alexion interim CEO says co is active on the business development front and is looking at opportunities Further company coverage: [ALXN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Alexion Pharmaceuticals posts Q4 adj. earnings $1.26/shr
Thursday, 16 Feb 2017 06:30am EST 

Alexion Pharmaceuticals Inc : Alexion reports fourth quarter and full year 2016 results and provides financial guidance for 2017 . Q4 non-GAAP earnings per share $1.26 . Q4 GAAP earnings per share $0.41 . Q4 revenue $831 million versus I/B/E/S view $836.6 million . Q4 earnings per share view $1.25 -- Thomson Reuters I/B/E/S . Alexion Pharmaceuticals Inc - board of directors has increased size of company's share repurchase authorization to a total of $1 billion . Sees 2017 total revenues $3,400 million to $3,500 million . Alexion Pharmaceuticals Inc - GAAP guidance for 2017 earnings per share $2.55 to $3.05 . Sees 2017 earnings per share non-GAAP $5.00 to $5.25 . FY2017 earnings per share view $5.54, revenue view $3.54 billion -- Thomson Reuters I/B/E/S .Alexion Pharmaceuticals Inc - board's repurchase authorization is open-ended.  Full Article

Alexion interim CEO says company is not up for sale - conf
Monday, 9 Jan 2017 11:59am EST 

Alexion Pharmaceuticals Inc : Alexion interim CEO says they are not up for sale - JPM Healthcare conf . Alexion execs says growth is primarily coming from volume, not pricing- JPM Healthcare conf . Alexion execs say they are going to be very careful with cash deployment for m&a - JPM Healthcare conf . Alexion says they are not aware of any more investigations into Soliris sales practices, other than what they have already revealed - JPM Healthcare conf Further company coverage: [ALXN.O] ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis
Monday, 9 Jan 2017 06:30am EST 

Alexion Pharmaceuticals Inc : Alexion submits U.S. and EU applications seeking approval of Soliris® (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis (gMG) .Alexion Pharmaceuticals Inc - Both U.S. and EU submissions are supported by comprehensive data from phase 3 regain study.  Full Article

Paulson & Co cuts share stake in Alexion Pharmaceuticals, Johnson & Johnson
Monday, 14 Nov 2016 05:38pm EST 

Paulson & Co : Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227,700 shares . Paulson & Co ups share stake in Fedex Corp by 47 percent to 106,800 shares . Paulson & Co takes 74,000 share stake in Alder Biopharmaceuticals Inc . Paulson & Co takes share stake of 628,100 shares in eBay Inc . Paulson & Co cuts share stake in Johnson & Johnson by 72.7 percent to 35,000 shares .Paulson & Co - change in holdings are as of September 30, 2016 and compared with the previous quarter ended as of June 30, 2016.  Full Article

Alexion gets orphan drug designation for ALXN1007
Monday, 29 Aug 2016 04:33pm EDT 

Alexion Pharmaceuticals Inc : European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD) .ALXN1007 is currently being evaluated in a phase 2 study in patients with newly diagnosed acute GI-GVHD.  Full Article

Alexion Pharmaceuticals-FDA recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode Island Manufacturing Facility
Monday, 8 Aug 2016 04:41pm EDT 

Alexion Pharmaceuticals Inc : Fda recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode island manufacturing facility . FDA observations also pertain to monitoring of water systems . Based on current information, alexion anticipates that supply of soliris to patients will not be interrupted . FDA observations pertain to completion, closure of certain investigations, validation of surface sampling methods .Based on current information, does not anticipate material financial impact to resolve outstanding fda concerns.  Full Article

More From Around the Web

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage: